PharmaEssentia is thrilled to announce that Health Canada has approved BESREMi® (ropeginterferon alfa-2b), a groundbreaking treatment offering new hope to patients battling polycythemia vera (PV), a rare and complex blood disorder
Browsing: clinical approval